V. COMPANY, MANAGEMENT & PROJECT (1) HISTORY, MAIN OBJECTS & PRESENT BUSINESS OF THE COMPANY Transgene Biotek Limited incorporated as a Private Limited Company on 1st March, 1990, was subsequently converted into Public Limited on 28th November, 1990. The Company is engaged in the research and development and manufacture of various medical reagents both Bio-chemical and Immuno-Diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in the Memorandum of Association are as under; 1. To undertake, promote, assist or engage in all kinds of development work required in the field of Bio-Technology, to develop the entire spectrum of diagnosis by Enzymatic or Chemical methods useful in Bio-Chemical assays, ELISA and EIA systems and to develop the monitoring equipment for diagnostic systems. 2. To develop, manufacture, buy, sell, import, export, and deal in all types of vaccines, enzyme sensors for medical and environment applications DNA related products like immuno modulators Genetic Engineering in medical and health sectors, antigens of infection agents. 3. To set up laboratories develop, extract, import, export buy sell, deal in hire, the technology, process methods systems and to manufacture import, export buy sell, deal in hire the equipment and instruments, chemicals and enzymes which are capable of being used in the fields of Bio-Technology genetic engineering and diagnosis. 4. To carry on the business of manufacturing, producing, refining, developing, processing, or otherwise acquiring, buying, selling, importing, exporting, marketing and generally dealing in all kinds of drugs, medicines, pharmaceuticals, antibiotics, herbal, bacteriogical, and biological products, chemicals of all kinds, laboratory reagents and other preparations, compounds and articles, all kinds of products and by-products arising there from and in connection there with and all implements substances, apparatus, materials, and things incidental to or useful in connection with any of such business. PRESENT BUSINESS The company has set up facilities for manufacture of Biochemical and Immuno diagnostic (ELISA, Latex agglutination & MIC ) reagents with present aggregate installed capacity of 168 lacs tests in Anrich Industrial Estate, Bollarum Medak dist. Andhra Pradesh. FINANCIAL PERFORMANCE OF THE COMPANY The company commenced commercial production from 1st OCT, '93. ----------------------------------------------------------- 1993-94 ----------------------------------------------------------- Capacity utilisation (%) 45.00 Production 94.68 Sales 252.91 Cost of production 177.31 PBIDT 75.78 Interest 41.91 Depreciation 13.44 PBT 20.42 PAT 20.42 Share Capital 340.00 Reserves 20.42 EPS (Rs) 0.60 Book Value 10.60 Break Even Point 36.68 ---------------------------------------------------------- 2011 - Company has set up a wholly-owned subsidiary Company in Hong Kong by the name "Transgene Biotek HK Ltd.". 2012 -"Transgene readying to launch one of its block-buster drugs - TrabiDHA (DHA) formulations." 2013 -Transgene signs a Joint Venture agreement with Atral Cipan of Portugal involving the technology transfer of Tacrolimus by Transgene. -Transgene Biotek becomes the world's first company to create and launch 50% algal DHA oil, and 20% algal DHA powder. 2014 -S/Sri Sarang Subhash Puranik and Shyam Shankar Das would be appointed as Directors of the company.